Tirzepatide for weight-linked endometrial cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have endometrial cancer and be scheduled for a hysterectomy.
- Your body mass index (BMI) must be 30 or higher.
- Your cancer must be early-stage and confined to the uterus.
- You must be 18 or older.
- You must agree to attend all study visits and have internet access.
- You cannot be taking certain medications that affect metabolism, including insulin for diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tirzepatide, a weekly injection that helps with weight loss and blood sugar control, can improve outcomes for women with obesity and early-stage endometrial cancer (or precancerous changes) who are scheduled for surgery. The goal is to see if taking this medication before surgery can help shrink the cancer or improve surgical results.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests whether the medicine tirzepatide, which is used for weight loss, can help women with early-stage endometrial cancer or a pre-cancerous condition avoid or delay surgery. It combines taking tizepatide with a hormonal intrauterine device (Mirena) to try to shrink or stop the cancer from growing.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.